| __timestamp | Iovance Biotherapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 12665000 |
| Thursday, January 1, 2015 | 999000 | 20202000 |
| Friday, January 1, 2016 | 978000 | 32407000 |
| Sunday, January 1, 2017 | 952000 | 35219000 |
| Monday, January 1, 2018 | 956000 | 36386000 |
| Tuesday, January 1, 2019 | 8122999 | 43081000 |
| Wednesday, January 1, 2020 | 8712000 | 39330000 |
| Friday, January 1, 2021 | 13980000 | 43283000 |
| Saturday, January 1, 2022 | 21135000 | 48316000 |
| Sunday, January 1, 2023 | 10755000 | 54634000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology and medical devices, understanding cost structures is crucial. From 2014 to 2023, Iovance Biotherapeutics, Inc. and MiMedx Group, Inc. have shown distinct trajectories in their cost of revenue. Iovance's cost of revenue surged by over 125% from 2014 to 2022, peaking in 2022 before a slight dip in 2023. This reflects their aggressive investment in R&D and scaling operations. Meanwhile, MiMedx Group, Inc. exhibited a steady increase, with a notable 330% rise over the same period, indicating robust growth and market expansion. The year 2023 marked MiMedx's highest cost of revenue, underscoring their commitment to innovation and market penetration. These trends highlight the dynamic nature of cost management in the biotech sector, offering insights into strategic financial planning and operational efficiency.
Cost of Revenue Trends: Novo Nordisk A/S vs MiMedx Group, Inc.
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Viatris Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and MiMedx Group, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Evotec SE
SG&A Efficiency Analysis: Comparing Iovance Biotherapeutics, Inc. and MiMedx Group, Inc.
Cost of Revenue Comparison: Wave Life Sciences Ltd. vs MiMedx Group, Inc.
Xencor, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored